Cojan Y, Vuilleumier P Functional brain imaging of psychogenic paralysis during conversion and hypnosis
Cojan Y, Waber L, Carruzzo A, Vuilleumier P Motor inhibition in hysterical conversion paralysis. Neuroimage. 2009 Sep;47(3):1026-37. doi: 10.1016/j.neuroimage.2009.05.023. Epub 2009 May 18.
de Lange FP, Roelofs K, Toni I Increased self-monitoring during imagined movements in conversion paralysis. Neuropsychologia. 2007 May 15;45(9):2051-8. Epub 2007 Feb 11.
de Lange FP, Roelofs K, Toni I Motor imagery: a window into the mechanisms and alterations of the motor system. Cortex. 2008 May;44(5):494-506. doi: 10.1016/j.cortex.2007.09.002. Epub 2007 Dec 23.
Desmurget M, Grafton S Forward modeling allows feedback control for fast reaching movements. Trends Cogn Sci. 2000 Nov 1;4(11):423-431.
Fourneret P, Jeannerod M Limited conscious monitoring of motor performance in normal subjects. Neuropsychologia. 1998 Nov;36(11):1133-40.
Sabes PN The planning and control of reaching movements. Curr Opin Neurobiol. 2000 Dec;10(6):740-6. Review.
Stone J, Carson A, Sharpe M Functional symptoms in neurology: management. J Neurol Neurosurg Psychiatry. 2005 Mar;76 Suppl 1:i13-21. Review.
van Beers RJ, Baraduc P, Wolpert DM Role of uncertainty in sensorimotor control. Philos Trans R Soc Lond B Biol Sci. 2002 Aug 29;357(1424):1137-45. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
